Look back at pharma news in week to Feb 16

By Barbara Obstoj-Cardwell

In the regulatory news sector last week, Vertex Pharmaceuticals came up with another drug approval, this time for Symdeko in cystic fibrosis. Two collaboration agreements attracted attention, most notably the record-breaking $3.6 billion deal between Nektar Therapeutics and Bristol-Myers Squibb focussed on its immuno-oncology candidate NKTR-214, but also Bioverativ’s accord with Oxford BioMedica on its LentiVector platform technology. There were two new questions in the Alzheimer’s disease space, those regarding Biogen with aducanumab and Merck & Co with verubecestat.

Vertex just keeps on impressing The Street with regulatory approvals